JP6952594B2 - 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 - Google Patents

細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 Download PDF

Info

Publication number
JP6952594B2
JP6952594B2 JP2017240652A JP2017240652A JP6952594B2 JP 6952594 B2 JP6952594 B2 JP 6952594B2 JP 2017240652 A JP2017240652 A JP 2017240652A JP 2017240652 A JP2017240652 A JP 2017240652A JP 6952594 B2 JP6952594 B2 JP 6952594B2
Authority
JP
Japan
Prior art keywords
gstp1
cancer
ras
craf
cell proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017240652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019108277A5 (enExample
JP2019108277A (ja
Inventor
洋司郎 新津
洋司郎 新津
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2017240652A priority Critical patent/JP6952594B2/ja
Priority to PCT/JP2018/045627 priority patent/WO2019117188A1/ja
Priority to US16/772,578 priority patent/US20200370050A1/en
Publication of JP2019108277A publication Critical patent/JP2019108277A/ja
Publication of JP2019108277A5 publication Critical patent/JP2019108277A5/ja
Priority to JP2021122479A priority patent/JP2021183618A/ja
Application granted granted Critical
Publication of JP6952594B2 publication Critical patent/JP6952594B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017240652A 2017-12-15 2017-12-15 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 Expired - Fee Related JP6952594B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2017240652A JP6952594B2 (ja) 2017-12-15 2017-12-15 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
PCT/JP2018/045627 WO2019117188A1 (ja) 2017-12-15 2018-12-12 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
US16/772,578 US20200370050A1 (en) 2017-12-15 2018-12-12 Cell proliferation inhibitor and cancer treatment or prevention pharmaceutical composition including cell proliferation inhibitor
JP2021122479A JP2021183618A (ja) 2017-12-15 2021-07-27 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017240652A JP6952594B2 (ja) 2017-12-15 2017-12-15 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021122479A Division JP2021183618A (ja) 2017-12-15 2021-07-27 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Publications (3)

Publication Number Publication Date
JP2019108277A JP2019108277A (ja) 2019-07-04
JP2019108277A5 JP2019108277A5 (enExample) 2020-09-24
JP6952594B2 true JP6952594B2 (ja) 2021-10-20

Family

ID=66820498

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017240652A Expired - Fee Related JP6952594B2 (ja) 2017-12-15 2017-12-15 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
JP2021122479A Pending JP2021183618A (ja) 2017-12-15 2021-07-27 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021122479A Pending JP2021183618A (ja) 2017-12-15 2021-07-27 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Country Status (3)

Country Link
US (1) US20200370050A1 (enExample)
JP (2) JP6952594B2 (enExample)
WO (1) WO2019117188A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
US20240141353A1 (en) * 2022-10-26 2024-05-02 David M. Evans Sirnas against kras and raf1
WO2025104494A2 (en) * 2023-11-13 2025-05-22 Versameb Ag Compositions and methods for modulating protein interactions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582995A (en) * 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
WO2009143372A2 (en) * 2008-05-21 2009-11-26 Intradigm Corporation Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof
EP2724729B1 (en) * 2011-06-21 2018-12-26 Nitto Denko Corporation Apoptosis-inducing agent
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
JP6864990B2 (ja) * 2015-04-16 2021-04-28 日東電工株式会社 Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物

Also Published As

Publication number Publication date
WO2019117188A1 (ja) 2019-06-20
JP2019108277A (ja) 2019-07-04
JP2021183618A (ja) 2021-12-02
US20200370050A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
TWI767883B (zh) 針對具有ｂｒａｆ基因突變之細胞之細胞死亡誘導劑、該細胞之增殖抑制劑及起因於該細胞之增殖異常之疾病之治療用醫藥組合物
CN107106564A (zh) 用于治疗与kras突变相关的恶性肿瘤的方法和组合物
KR20140041770A (ko) 아포토시스 유도제
CN103842508A (zh) 白蛋白产生和细胞增殖
WO2015005473A1 (ja) がんの治療への応答性を予測する方法
JP2021183618A (ja) 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
CN113827727B (zh) Ptpn2抑制剂在kras突变肿瘤中的应用
Diazzi et al. Blockade of the pro‐fibrotic reaction mediated by the miR‐143/‐145 cluster enhances the responses to targeted therapy in melanoma
Suresh et al. AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
TWI812591B (zh) 細胞死亡誘導劑、細胞增殖抑制劑及起因於細胞之增殖異常之疾病之治療用醫藥組合物
JP2014112096A (ja) がん患者の予後推定用バイオマーカー及びその利用
US20110060029A1 (en) Method of treating cancer by modulating epac
CN115177728B (zh) Mapk/erk通路激活导致的癌症的治疗方法和应用及crept-cdk9复合物
EP3658158A1 (en) Smac/diablo inhibitors useful for treating cancer
JP6768979B2 (ja) Ｈｓｐ４７の阻害物質を用いた、がん転移抑制
CN101039694A (zh) 新治疗蛋白质和靶标e2－epf5
US8486905B2 (en) Use of FLJ25416 gene
CN116271056A (zh) 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物
WO2020009189A1 (ja) Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤
Baldwin The role of atypical protein kinase C iota in glioblastoma multiforme
JP2019165706A (ja) がんの治療又は予防用医薬および癌のバイオマーカー

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190529

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200817

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210803

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210928

R150 Certificate of patent or registration of utility model

Ref document number: 6952594

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees